Seid Getachew, Alemu Ayinalem, Tsedalu Tsegaye, Dagne Biniyam
Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
IJID Reg. 2022 Jun 23;4:97-104. doi: 10.1016/j.ijregi.2022.06.004. eCollection 2022 Sep.
Tuberculosis (TB) is a global burden, and this is likely to remain the case due to a lack of adequate and accurate point-of-care diagnostic tests. Obtaining good-quality sputum from the bottom of the respiratory tract of children is challenging. Lipoarabinomannan (LAM) is a specific component of the mycobacterial cell envelope that is excreted in the urine of people with active TB. This study aimed to assess the performance of different types of urine-based LAM antigen tests for the diagnosis of TB in children.
Relevant databases were searched for studies that used urine-based LAM tests to diagnose TB in children. Study quality was assessed using the Joanna Briggs Institute Critical Appraisal Tool. Pooled sensitivity and specificity were calculated using the random-effect model in STATA Version 16.0. Moreover, subgroup analysis was undertaken to hinder the heterogeneity of the studies.
Eleven articles were included in the final systematic review and meta-analysis. The pooled sensitivity and specificity of the enzyme-linked immunosorbent assay (MTB-LAM-ELISA), Alere Determine TB LAM Ag (Alere LAM) test and the Fujifilm SILVAMP TB LAM (Fuji LAM) test in children aged <15 years with TB were 16.0% [95% confidence interval (CI) 10.25-42.25] and 95.61% (95% CI 93.74-97.74); 45.90% (95% CI 40.40-51.40) and 80.42% (95% CI 69.39-91.46); and 52.32% (95% CI 35.03-69.62) and 89.37% (95% CI 82.88-95.86), respectively. Subgroup analysis revealed that the pooled sensitivity and specificity of MTB-LAM-ELISA, Alere LAM test and Fuji LAM test were 33.5% (95% CI 34.86-100) and 95.83% (95% CI 91.50-100); 46.59% (95% CI 32.98-60.19) and 76.45% (95% CI 57.07-95.82); and 57.89% (95% CI 48.44-67.35%) and 87.66% (95% CI 75.29-100), respectively, in human immunodeficiency virus (HIV)-positive children; and 3.35% (95% CI 1.61-8.31) and 96.0% (95% CI 93.88-98.11); 32.33% (95% CI 7.63-57.03) and 79.07% (95% CI 62.62-95.51); and 50.95% (95% CI 27.45-74.45) and 89.47% (95% CI 84.72-94.22), respectively, in HIV-negative children.
The Fuji LAM and Alere LAM tests may be useful for the diagnosis of TB in children in conjunction with other more sensitive and specific tests, although a prospective study in relevant clinical settings is needed to evaluate this. There is a need for more evidence-based data on the use of these rapid diagnostic tools to diagnose TB in children independent of HIV status.
结核病是一项全球负担,由于缺乏足够准确的即时诊断检测,这种情况可能会持续存在。从儿童呼吸道深处获取高质量痰液具有挑战性。脂阿拉伯甘露聚糖(LAM)是分枝杆菌细胞壁的一种特定成分,在活动性结核病患者的尿液中排泄。本研究旨在评估不同类型基于尿液的LAM抗原检测在儿童结核病诊断中的性能。
检索相关数据库,查找使用基于尿液的LAM检测诊断儿童结核病的研究。使用乔安娜·布里格斯研究所批判性评价工具评估研究质量。使用STATA 16.0版中的随机效应模型计算合并敏感性和特异性。此外,进行亚组分析以减少研究的异质性。
最终的系统评价和荟萃分析纳入了11篇文章。酶联免疫吸附测定(MTB-LAM-ELISA)、Alere Determine TB LAM Ag(Alere LAM)检测和富士胶片SILVAMP TB LAM(Fuji LAM)检测在15岁以下结核病儿童中的合并敏感性和特异性分别为16.0%[95%置信区间(CI)10.25 - 42.25]和95.61%(95% CI 93.74 - 97.74);45.90%(95% CI 40.40 - 51.40)和80.42%(95% CI 69.39 - 91.46);以及52.32%(95% CI 35.03 - 69.62)和89.37%(95% CI 82.88 - 95.86)。亚组分析显示,MTB-LAM-ELISA、Alere LAM检测和Fuji LAM检测在人类免疫缺陷病毒(HIV)阳性儿童中的合并敏感性和特异性分别为33.5%(95% CI 34.86 - 100)和95.83%(95% CI 91.50 - 100);46.59%(95% CI 32.98 - 60.19)和76.45%(95% CI 57.07 - 95.82);以及57.89%(95% CI 48.44 - 67.35%)和87.66%(95% CI 75.29 - 100);在HIV阴性儿童中分别为3.35%(95% CI 1.61 - 8.31)和96.0%(95% CI 93.88 - 98.11);32.33%(95% CI 7.63 - 57.03)和79.07%(95% CI 62.62 - 95.51);以及50.95%(95% CI 27.45 - 74.45)和89.47%(95% CI 84.72 - 94.22)。
Fuji LAM和Alere LAM检测可能与其他更敏感和特异 的检测方法联合用于儿童结核病的诊断,不过需要在相关临床环境中进行前瞻性研究来评估这一点。需要更多基于证据的数据来确定这些快速诊断工具在不考虑HIV状态的情况下用于儿童结核病诊断的情况。